The CUHK research group led by Professor Tony Mok Shu-kam has decoded the common mutated genes in lung cancer and developed targeted therapies that have successfully increased patients’ lifespans. These innovative therapies redefined global paradigms in lung cancer treatment, providing patients with fresh hope. Professor Mok has established himself as one of the leading oncologists of the world, with his work on targeted EGFR inhibitors marking a significant milestone in the use of immunotherapy.
A new chapter is opening in cancer immunotherapy. A first-in-human clinical trial of CRISPR technology to treat late stage lung cancer has proved safe by a CUHK joint research. T-Cells of advanced condition patients have been extracted, gene edited and reinfused as potential fighters against cancer cells.